Skip to main content
OpenTrials
Active, Not Recruiting

NCT Number: NCT06512337

A Observational Study to Evaluate Deucravacitinib in Patients With Moderate Plaque Psoriasis in China

The purpose of this study is to collect and evaluate real-world data on the effectiveness of deucravacitinib treatment in adults with moderate plaque psoriasis in China.

Active, Not Recruiting

This study is active but is not currently recruiting participants.

Notify Me

Key information

Conditions

Plaque Psoriasis

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Local Institution - 0001, Guangzhou, Guangdong, China

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Participant aged 18 years or older
  • Physician-reported (dermatologist) diagnosis of moderate plaque psoriasis with Body Surface Area ≥ 3% and < 10%
  • Participant newly initiated deucravacitinib according to the label
  • Provided written informed consent to participate in the study

Exclusion criteria

  • Participating in or planning to participate in an interventional clinical trial
  • Concomitant use of other systemic treatments for psoriasis at baseline
  • Prior treatment of deucravacitinib

Treatment and study plan

Deucravacitinib

Drug

As per product label

Primary outcomes

  1. Number of participants achieving Static Physician's Global Assessment (sPGA) 0/1 score

    Time frame: Week 16

  2. Participant psoriasis Body Surface Area (BSA) involvement

    Time frame: Week 16

  3. Number of participants achieving absolute Psoriasis Area and Severity Index (PASI) score ≤ 3

    Time frame: Week 16

Secondary outcomes

  1. Number of participants achieving Psoriasis Area and Severity Index (PASI) 75 response and PASI 90 response

    Time frame: Baseline and Weeks 4, 12, 24, 36, and 52

  2. Number of participants achieving absolute Psoriasis Area and Severity Index (PASI) score ≤1, ≤2, ≤3, and ≤5

    Time frame: Baseline and Weeks 4, 12, 24, 36, and 52

  3. Participants change in Participant Absolute Psoriasis Area and Severity Index (PASI) score from baseline

    Time frame: Weeks 4, 12, 16, 24, 36, and 52

  4. Number of participants achieving psoriasis Body Surface Area (BSA) involvement of ≤1% and ≤3%

    Time frame: Baseline and Weeks 4, 12, 16, 24, 36, and 52

  5. Change in Body Surface Area (BSA) involvement from baseline to follow-up

    Time frame: Weeks 4, 12, 24, 36, and 52

  6. Static Physician's Global Assessment (sPGA) 0/1 response at follow-up

    Time frame: Weeks 4, 12, 24, 36, and 52

  7. Participants change in Static Physician's Global Assessment (sPGA) score from baseline

    Time frame: Baseline and Weeks 4, 12, 16, 24, 36, and 52

  8. Number of participants achieving a Dermatology Life Quality Index (DLQI) 0/1 score

    Time frame: Baseline and Weeks 4, 12, 16, 24, 36, and 52

  9. Number of participants achieving a Dermatology Life Quality Index (DLQI) ≤ 3 score

    Time frame: Baseline and Weeks 4, 12, 16, 24, 36, and 52

  10. Change in participant Dermatology Life Quality Index (DLQI) score from baseline

    Time frame: Baseline and Weeks 4, 12, 16, 24, 36, and 52

Sponsors and collaborators

Lead sponsor

Bristol-Myers Squibb

Industry

Registry information

Official study title

A Prospective Observational Study to Evaluate the Effectiveness of Deucravacitinib in Patients With Moderate Plaque Psoriasis in Real-World Settings in China (ADMIRE)

Acronym: ADMIRE

Important dates

Study start
2025
Primary completion
2027
Study completion
2027
First posted
Jul 22, 2024
Registry last updated
Apr 15, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.